Olszewski Sławomir, Olszewska Ewa, Popko Janusz, Poskrobko Elżbieta, Sierakowski Stanisław, Zwierz Krzysztof
Department of Orthopedics and Traumatology, Bialystok Hospital, Poland.
Department of Otolaryngology, Medical University of Bialystok, Poland.
Adv Clin Exp Med. 2015 Sep-Oct;24(5):807-13. doi: 10.17219/acem/27302.
The effect of multiple infusions of infliximab (INF), a chimeric anti-tumor necrosis factor alpha antibody, on the concentration of hexosaminidase (HEX) activity in a synovial cell culture derived from human synovial inflamed fluid obtained from patients suffering from rheumatoid arthritis (RA) has been evaluated.
The aim of this study was to prove INF efficacy in RA.
Inflamed synovial fluid was taken from RA patients (a study group) and patients who had undergone knee trauma within 7 days (a control group). The following solutions of infliximab were used: 40, 60 and 140 µg/mL. Determination of the concentration of HEX activity in cell cultures was performed after 24, 48, 72 and 96 h of infliximab administration. To identify synoviocytes in cell culture immunohistochemical staining with vimentin and pancytokeratin was performed.
A predominance of fibroblast-like synovial cells has been observed in the study group. In the control group the concentration of HEX activity without adding infliximab to the cell culture was 283.00 nkat/mL. After 96 h of incubation with infliximab, the concentrations of HEX activity in cultured synoviocytes according to infliximab doses of 40, 60 and 140 µg/mL were respectively: 280.00, 271.50 and 293.50 nkat/mL. In the study group, the concentration of HEX activity without adding infliximab to the cell culture was 542.27 nkat/mL. The final concentrations of HEX activity of cultured fibroblast-like synovial cells measured after 96 h of incubation with infliximab were: 471.72, 498.27 and 556.72 nkat/mL, according to infliximab doses of 40, 60 and 140 µg/mL. In all groups (besides the infliximab concentration of 140 µg/mL after 96 h of incubation), the level of concentration of HEX activity was significantly higher in the study group compared to the control group, irrespective of infliximab concentration and time of infliximab incubation.
Infliximab changes the concentration of HEX activity depending on the drug dose and time of administration.
已评估多次输注英夫利昔单抗(INF),一种嵌合型抗肿瘤坏死因子α抗体,对源自类风湿性关节炎(RA)患者炎症滑膜液的滑膜细胞培养物中己糖胺酶(HEX)活性浓度的影响。
本研究的目的是证明英夫利昔单抗在类风湿性关节炎中的疗效。
从类风湿性关节炎患者(研究组)和7天内膝关节受伤的患者(对照组)获取炎症滑膜液。使用以下英夫利昔单抗溶液:40、60和140μg/mL。在给予英夫利昔单抗24、48、72和96小时后,测定细胞培养物中HEX活性的浓度。为了识别细胞培养物中的滑膜细胞,进行了波形蛋白和全细胞角蛋白的免疫组织化学染色。
在研究组中观察到成纤维细胞样滑膜细胞占优势。在对照组中,细胞培养物中未添加英夫利昔单抗时HEX活性浓度为283.00nkat/mL。与英夫利昔单抗40、60和140μg/mL剂量孵育96小时后,培养的滑膜细胞中HEX活性浓度分别为:280.00、271.50和293.50nkat/mL。在研究组中,细胞培养物中未添加英夫利昔单抗时HEX活性浓度为542.27nkat/mL。与英夫利昔单抗40、60和140μg/mL剂量孵育96小时后,培养的成纤维细胞样滑膜细胞中HEX活性的最终浓度分别为:471.72、498.27和556.72nkat/mL。在所有组中(除了孵育96小时后英夫利昔单抗浓度为140μg/mL的情况),无论英夫利昔单抗浓度和孵育时间如何,研究组中HEX活性浓度水平均显著高于对照组。
英夫利昔单抗根据药物剂量和给药时间改变HEX活性浓度。